title: ÐÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ðµ ÐºÐ»Ð¸Ð½Ð¸ÑÐµÑÐºÐ¸ Ð·Ð½Ð°ÑÐ¸Ð¼ÑÑ ÑÑÐ°Ð½ÑÐ»Ð¾ÐºÐ°ÑÐ¸Ð¹ Ð¿ÑÐ¸ ÑÐ°ÐºÐµ Ð¿Ð¾Ð´Ð¶ÐµÐ»ÑÐ´Ð¾ÑÐ½Ð¾Ð¹ Ð¶ÐµÐ»ÐµÐ·Ñ
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Investigation of clinically relevant translocations in pancreatic cancer
Creators: name: Ð¨ÐµÐ²ÑÐºÐ¾Ð², ÐÐ¸ÑÐ°Ð¸Ð»
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2023
Subjects: ÑÐ°Ðº Ð¿Ð¾Ð´Ð¶ÐµÐ»ÑÐ´Ð¾ÑÐ½Ð¾Ð¹ Ð¶ÐµÐ»ÐµÐ·Ñ
ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ½ÑÐµ ÑÐ¸ÑÐ¾Ð·Ð¸Ð½ÐºÐ¸Ð½Ð°Ð·Ñ
ÑÑÐ°Ð½ÑÐ»Ð¾ÐºÐ°ÑÐ¸Ñ
ÑÐ°ÑÐ³ÐµÑÐ½Ð°Ñ ÑÐµÑÐ°Ð¿Ð¸Ñ
ÐÐ¦Ð Ð² ÑÐµÐ°Ð»ÑÐ½Ð¾Ð¼ Ð²ÑÐµÐ¼ÐµÐ½Ð¸
pancreatic cancer
receptor tyrosine kinases
translocations
target therapy
real-time PCR

description: ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ ÑÑÐ°Ð½ÑÐ»Ð¾ÐºÐ°ÑÐ¸Ð¹, Ð°ÑÑÐ¾ÑÐ¸Ð¸ÑÐ¾Ð²Ð°Ð½Ð½ÑÑ Ñ Ð¾Ð¿ÑÑÐ¾Ð»ÑÑ Ð¿Ð¾Ð´Ð¶ÐµÐ»ÑÐ´Ð¾ÑÐ½Ð¾Ð¹ Ð¶ÐµÐ»ÐµÐ·Ñ Ñ ÑÐµÐ»ÑÑ Ð¿Ð¾Ð¸ÑÐºÐ° ÑÐ¿ÐµÑÐ¸ÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð¼Ð¸ÑÐµÐ½ÐµÐ¹ Ð´Ð»Ñ Ð½Ð°Ð·Ð½Ð°ÑÐµÐ½Ð¸Ñ ÑÐ°ÑÐ³ÐµÑÐ½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸. ÐÐ»Ñ Ð´Ð¾ÑÑÐ¸Ð¶ÐµÐ½Ð¸Ñ Ð¿Ð¾ÑÑÐ°Ð²Ð»ÐµÐ½Ð½Ð¾Ð¹ ÑÐµÐ»Ð¸ Ð±ÑÐ»Ð¸ Ð¿ÑÐ¸Ð¼ÐµÐ½ÐµÐ½Ñ ÑÐ»ÐµÐ´ÑÑÑÐ¸Ðµ Ð¼ÐµÑÐ¾Ð´Ñ: Ð°Ð½Ð°Ð»Ð¸Ð· Ð¿Ð»Ð°Ð²Ð»ÐµÐ½Ð¸Ñ Ð²ÑÑÐ¾ÐºÐ¾Ð³Ð¾ ÑÐ°Ð·ÑÐµÑÐµÐ½Ð¸Ñ (HRM), Ð°Ð»Ð»ÐµÐ»Ñ-ÑÐ¿ÐµÑÐ¸ÑÐ¸ÑÐµÑÐºÐ°Ñ ÐÐ¦Ð  (AS-PCR), ÑÐ¸ÑÑÐ¾Ð²Ð°Ñ ÐºÐ°Ð¿ÐµÐ»ÑÐ½Ð°Ñ ÐÐ¦Ð  (Digital droplet PCR), Ð¾Ð±ÑÐ°ÑÐ½Ð¾-ÑÑÐ°Ð½ÑÐºÑÐ¸Ð¿ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÐÐ¦Ð  (RT-PCR), ÐÐ¦Ð  Ð² ÑÐµÐ°Ð»ÑÐ½Ð¾Ð¼ Ð²ÑÐµÐ¼ÐµÐ½Ð¸ (Real-time PCR). Ð ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐµ ÑÐµÑÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ ÑÐ´Ð°Ð»Ð¾ÑÑ Ð²ÑÑÐ²Ð¸ÑÑ 5 Ð¿Ð¾Ð·Ð¸ÑÐ¸Ð²Ð½ÑÑ ÑÐ»ÑÑÐ°Ñ, Ð´ÐµÐ¼Ð¾Ð½ÑÑÑÐ¸ÑÑÑÑÐ¸Ñ Ð´Ð¸ÑÐ±Ð°Ð»Ð°Ð½Ñ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð¿ÐµÑÐµÑÑÑÐ°Ð¸Ð²Ð°ÐµÐ¼ÑÑ Ð³ÐµÐ½Ð¾Ð² (3 ÑÐ»ÑÑÐ°Ñ ALK, 1 â RET, 1 â NTRK1). Ð¡ Ð¿Ð¾Ð¼Ð¾ÑÑÑ Ð²Ð°ÑÐ¸Ð°Ð½Ñ-ÑÐ¿ÐµÑÐ¸ÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐÐ¦Ð  Ð±ÑÐ»Ð¸ Ð¾Ð¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ñ Ð¿ÐµÑÐµÑÑÑÐ¾Ð¹ÐºÐ¸ EML4-ALK (E13;A20), NCOA4-RET (N7;R12), Ð¾ÑÑÐ°Ð²ÑÐ¸ÐµÑÑ 2 ÑÐ»ÑÑÐ°Ñ ÑÐ¾Ð´ÐµÑÐ¶Ð°Ð»Ð¸ ÑÐµÐ´ÐºÐ¸Ðµ ÑÐ¸Ð¼ÐµÑÐ½ÑÐµ ÑÑÐ°Ð½ÑÐºÑÐ¸Ð¿ÑÑ, ÐºÐ¾ÑÐ¾ÑÑÐµ Ð±ÑÐ»Ð¸ Ð¸Ð´ÐµÐ½ÑÐ¸ÑÐ¸ÑÐ¸ÑÐ¾Ð²Ð°Ð½Ñ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ ÑÐ°ÑÐ³ÐµÑÐ½Ð¾Ð³Ð¾ NGS-ÑÐµÐºÐ²ÐµÐ½Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ: COL1A1-ALK (C25;del50A20), GCC2-ALK (G7;A20), GP2-NTRK1 (G3;N8). ÐÐ°Ð¶Ð½Ð¾ Ð·Ð°Ð¼ÐµÑÐ¸ÑÑ, ÑÑÐ¾ Ð² Ð´Ð°Ð½Ð½ÑÑ Ð¾Ð±ÑÐ°Ð·ÑÐ°Ñ Ð½Ðµ Ð±ÑÐ»Ð¾ Ð²ÑÑÐ²Ð»ÐµÐ½Ð¾ Ð¼ÑÑÐ°ÑÐ¸Ð¹ Ð² Ð³ÐµÐ½Ðµ KRAS, ÑÑÐ¾ Ð´Ð¾Ð¿Ð¾Ð»Ð½Ð¸ÑÐµÐ»ÑÐ½Ð¾ Ð¿Ð¾Ð´ÑÐ²ÐµÑÐ¶Ð´Ð°ÐµÑ Ð½Ð°ÑÑ Ð³Ð¸Ð¿Ð¾ÑÐµÐ·Ñ Ð¾ ÑÐ¾Ð¼, ÑÑÐ¾ ÑÑÐ°ÑÑÑ Ð¼ÑÑÐ°ÑÐ¸Ð¸ KRAS Ð¼Ð¾Ð¶ÐµÑ Ð±ÑÑÑ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½ ÐºÐ°Ðº Ð¿ÑÐµÐ´Ð¸ÐºÑÐ¸Ð²Ð½ÑÐ¹ Ð¼Ð°ÑÐºÐµÑ Ð´Ð»Ñ Ð¾Ð¿ÑÐ¸Ð¼Ð¸Ð·Ð°ÑÐ¸Ð¸ Ð¿Ð¾Ð¸ÑÐºÐ° ÑÑÐ°Ð½cÐ»Ð¾ÐºÐ°ÑÐ¸Ð¹. Ð¢Ð°ÐºÐ¸Ð¼ Ð¾Ð±ÑÐ°Ð·Ð¾Ð¼, ÑÐµÑÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð¸Ðµ KRAS-Ð½ÐµÐ³Ð°ÑÐ¸Ð²Ð½ÑÑ Ð¾Ð±ÑÐ°Ð·ÑÐ¾Ð² Ð ÐÐ ÑÐ²Ð»ÑÐµÑÑÑ Ð¿ÐµÑÑÐ¿ÐµÐºÑÐ¸Ð²Ð½Ð¾Ð¹ Ð·Ð°Ð´Ð°ÑÐµÐ¹, ÑÐ°Ðº ÐºÐ°Ðº Ð²ÑÑÐ²Ð»ÐµÐ½Ð¸Ðµ Ð½Ð¾Ð²ÑÑ Ð¼Ð¸ÑÐµÐ½ÐµÐ¹ Ð´Ð»Ñ ÑÐ°ÑÐ³ÐµÑÐ½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ð¼Ð¾Ð¶ÐµÑ ÑÑÐ³ÑÐ°ÑÑ ÐºÐ»ÑÑÐµÐ²ÑÑ ÑÐ¾Ð»Ñ Ð² Ð¾ÑÐ½Ð¾ÑÐµÐ½Ð¸Ð¸ ÑÐ»ÑÑÑÐµÐ½Ð¸Ñ Ð²ÑÐ¶Ð¸Ð²Ð°ÐµÐ¼Ð¾ÑÑÐ¸ Ð¿ÑÐ¸ Ð´Ð°Ð½Ð½Ð¾Ð¼ ÑÐ¸Ð¿Ðµ Ð·Ð»Ð¾ÐºÐ°ÑÐµÑÑÐ²ÐµÐ½Ð½Ð¾Ð³Ð¾ Ð½Ð¾Ð²Ð¾Ð¾Ð±ÑÐ°Ð·Ð¾Ð²Ð°Ð½Ð¸Ñ.
description: The current research is devoted to study of translocations associated with pancreatic tumors in order to find specific targets for the prescription of targeted therapy. The following methods were used to achieve this aim: high resolution melting analysis (HRM), allele specific PCR (AS-PCR), digital droplet PCR, reverse transcriptional PCR (RT-PCR), real-time PCR. Testing revealed 5 positive cases showing an imbalance in the expression of rearranged genes (3 cases ALK, 1 case RET, 1 case NTRK1). Using variant-specific PCR, rearrangements of EML4-ALK (E13;A20), NCOA4-RET (N7;R12) were identified, the remaining 2 cases contained rare chimeric transcripts that were identified by targeted NGS sequencing: COL1A1-ALK (C25;del50A20),Â  GCC2-ALK (G7;A20), GP2-NTRK1 (G3;N8). It is important to note that no mutations in the KRAS gene were detected in these samples, which further supports our hypothesis that KRAS mutation status can be used as a predictive marker to optimise translocation search. Thus, testing KRAS negative samples of pancreatic cancer is a promising task, as the identification of new targets for targeted therapies may play a key role with respect to improving survival in this type of malignancy.